Endocrine Abstracts

Actuality: Type 2 diabetes mellitus patients have a higher risk of developing severe liver disease compared with non-diabetes patients. According to the data, among patients with type 2 diabetes, the incidence of cardiovascular, cerebrovascular and peripheral vascular diseases, as well as nephropathy and retinopathy, is significantly higher in the case of concomitant NAFLD. The fact of liver damage in T2DM is beyond doubt. The liver plays a key role in all metabolic processes and at the same time is a target in the formation and progression of metabolic disorders, in particular, insulin resistance.

Purpose: To study the feature of the instrumental method for the diagnosis of FibroScan in patients with type 2 diabetes with NAFLD.

Materials and methods: 40 patients were examined. 20 patients with type 2 diabetes and NAS and 20 patients type 2 diabetes and NASH. All patients underwent measurements of liver stiffness using a FibroScan. Average age: 56 ± 4.6; Hb1c-9.5%; BMI-30.2 kg/m²; Diabetes experience 7 ± 2.3 years.

Results: In patients with type 2 diabetes and NAS, F0 was more often detected 42%, and in patients with type 2 diabetes and NASH, F1 was detected 29%. According to the results of FibroScan, the degree of F4 fibrosis was more common in patients with type 2 diabetes and NASH 11%, respectively 4%. The average value of steatosis in 40 patients was: S0-1-2 (5%), S2 – 33 (82.5%), S3-5 (13.5%).

Conclusion: According to our study, fibrotic changes were more common in patients with type 2 diabetes and NASH. Liver FibroScan is an effective approach for the diagnosis of liver fibrosis in patients with type 2 diabetes and NAFLD